BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 25132017)

  • 1. The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil.
    Liu Y; Li X; Xin S; Xu Z; Chen R; Yang J; Liu L; Wong VW; Yang D; Chan HL; Xu D
    J Viral Hepat; 2015 Mar; 22(3):328-34. PubMed ID: 25132017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.
    Liu Y; Liu W; Li X; Xu Z; Wang X; Li C; Chen L; Xin S; Xu D
    Antivir Ther; 2014; 19(6):551-8. PubMed ID: 24710668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased occurrence of mutant rtI233V of HBV in patients receiving adefovir therapy.
    Liu Y; Xin S; Ye X; Chen R; Xu Z; Li X; Ye H; Cheng S; Xu D
    Antivir Ther; 2016; 21(1):9-16. PubMed ID: 26079809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
    Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
    Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).
    Osiowy C; Villeneuve JP; Heathcote EJ; Giles E; Borlang J
    J Clin Microbiol; 2006 Jun; 44(6):1994-7. PubMed ID: 16757589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
    Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
    Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
    Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
    Svarovskaia ES; Curtis M; Zhu Y; Borroto-Esoda K; Miller MD; Berg T; Lavocat F; Zoulim F; Kitrinos KM
    J Viral Hepat; 2013 Feb; 20(2):131-40. PubMed ID: 23301548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The rate of hepatitis B virus resistance to adefovir dipivoxil (ADV) and the evolution of hepatitis B virus in lamivudine-resistant chronic hepatitis B patients with ADV monotherapy].
    Qin YL; Zhang JM; Huang YX; Mao RC; Yin YK; Zhang WQ; Zhang QB; Wu XH; Weng XH
    Zhonghua Gan Zang Bing Za Zhi; 2007 Jan; 15(1):4-7. PubMed ID: 17244449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
    Cho YK; Cui XJ; Jeong SU; Song BC
    Antiviral Res; 2014 Dec; 112():8-17. PubMed ID: 25303802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients.
    Chen R; Liu Y; Luo D; Si L; Huang B; Wang J; Li X; Cheng F; Xu D; Duan C
    Antiviral Res; 2020 Aug; 180():104852. PubMed ID: 32569703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of therapy in patients with chronic hepatitis B virus.
    Arrese E; Basaras M; Blanco S; Ruiz P; Cisterna R
    Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):736-40. PubMed ID: 19550344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dissection of mechanism for the adefovir dipivoxil resistance in chronic hepatitis B patients].
    Zeng AZ; Lu P; Deng H; Cai SF; Yang C; Xin XJ; Guo JJ; Li QL; Deng XH; Huang AL
    Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):730-4. PubMed ID: 19874686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
    Yatsuji H; Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Watahiki S; Iwasaki S; Kobayashi M; Kumada H
    J Hepatol; 2008 Jun; 48(6):923-31. PubMed ID: 18433925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
    Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
    Qi X; Xiong S; Yang H; Miller M; Delaney WE
    Antivir Ther; 2007; 12(3):355-62. PubMed ID: 17591025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
    Inoue J; Ueno Y; Wakui Y; Niitsuma H; Fukushima K; Yamagiwa Y; Shiina M; Kondo Y; Kakazu E; Tamai K; Obara N; Iwasaki T; Shimosegawa T
    J Viral Hepat; 2011 Mar; 18(3):206-15. PubMed ID: 20367795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B.
    Liu LJ; Wang JH; Du SC; Tian JH; Yang RF; Wei L
    J Viral Hepat; 2010 Mar; 17 Suppl 1():66-72. PubMed ID: 20586936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants.
    Carrouée-Durantel S; Durantel D; Werle-Lapostolle B; Pichoud C; Naesens L; Neyts J; Trépo C; Zoulim F
    Antivir Ther; 2008; 13(3):381-8. PubMed ID: 18572751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.